Perrigo Company plc (NYSE:PRGO) Receives Average Rating of “Hold” from Analysts

Shares of Perrigo Company plc (NYSE:PRGO) have received an average recommendation of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $19.3333.

PRGO has been the topic of several analyst reports. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th.

Institutional Investors Weigh In On Perrigo

A number of large investors have recently added to or reduced their stakes in PRGO. Handelsbanken Fonder AB increased its stake in shares of Perrigo by 20.7% during the second quarter. Handelsbanken Fonder AB now owns 50,200 shares of the company’s stock worth $522,000 after purchasing an additional 8,600 shares during the period. GAMMA Investing LLC increased its position in Perrigo by 58.3% during the 2nd quarter. GAMMA Investing LLC now owns 14,733 shares of the company’s stock worth $153,000 after buying an additional 5,427 shares during the period. Bank of America Corp DE lifted its holdings in shares of Perrigo by 25.5% during the first quarter. Bank of America Corp DE now owns 1,568,598 shares of the company’s stock worth $16,847,000 after buying an additional 318,248 shares in the last quarter. RBF Capital LLC bought a new stake in shares of Perrigo in the first quarter valued at about $1,933,000. Finally, Parvin Asset Management LLC grew its stake in shares of Perrigo by 51.4% in the first quarter. Parvin Asset Management LLC now owns 19,875 shares of the company’s stock valued at $213,000 after acquiring an additional 6,750 shares in the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 1.5%

Shares of NYSE PRGO traded down $0.16 during mid-day trading on Thursday, reaching $10.27. 101,630 shares of the company’s stock were exchanged, compared to its average volume of 3,168,974. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -0.78, a PEG ratio of 1.22 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The business has a fifty day simple moving average of $10.57 and a 200 day simple moving average of $11.68. Perrigo has a twelve month low of $9.23 and a twelve month high of $27.33.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The firm’s revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities analysts expect that Perrigo will post 2.11 EPS for the current fiscal year.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.